SAN DIEGO, January 31, 2014 – Profil Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, celebrates its ten year anniversary.
Profil Institute began operations in 2004, fulfilling an important need in the U.S. market as a science driven clinical research organization focused on diabetes and obesity. As Profil Institute expanded its reputation based on its scientific expertise, the company’s client base grew to include today’s largest pharmaceutical companies.
Since the company’s inception, Profil Institute has completed over 200 diabetes and obesity phase I-IIa clinical studies. Additionally, the company has performed research within every clinically relevant drug class in diabetes. Profil Institute has assembled a portfolio of methodologies for metabolic clinical research and development unrivaled by any other early phase CRO.
“As a team, we are celebrating a decade of outstanding accomplishments in science, clinical research, and positively impacting the lives of people affected by diabetes,” said Dr. Marcus Hompesch, Profil Institute President and CEO.
About Profil® Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is an early phase clinical research organization focused on diabetes and obesity. The company is renowned as a center of excellence for metabolic clinical research and development based on its scientific expertise, end-to-end early phase services, and research methodologies. Profil Institute has completed more than 200 phase I-IIa diabetes and obesity clinical programs involving every clinically relevant diabetes drug class and medical device in the last decade. For more information, visit www.profilinstitute.com.
For general inquiries, please contact:
2004 – 2014